Peptidomimetic research compound · Fact sheet

Dihexa

Also known as PNB-0408 · Dihexa acetate

Dihexa is an experimental peptidomimetic studied for nerve-cell signaling and cognition in laboratory models. It has no established human cognitive benefit or FDA-approved use, and human safety information is inadequate.

Preclinical researchMostly animal or lab research

What is Dihexa?

Dihexa is derived from angiotensin-related peptide research and interacts with hepatocyte growth factor signaling through c-Met. It is distinct from other compounds developed around the same pathway.

Benefits & claims

Memory, learning, and brain repair are common claims. New synaptic connections in a laboratory system do not show that a person will think better or recover from a neurological disease.

What the evidence supports

  • Preclinical work links Dihexa to synapse-related changes and animal learning measures.
  • Protective effects in zebrafish sensory hair cells provide an additional research question, not a clinical indication.
Research areas
  • HGF/c-Met signaling
  • Synaptic plasticity
  • Experimental cognition
  • Hair-cell protection models

Dosage & frequency

No established human regimen

Dihexa is a preclinical small molecule. Reviewed evidence does not establish a human dose, frequency, or clinical cognitive benefit.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Animal cognition experiments do not establish a human nootropic regimen.

Interactions & precautions

  • Human drug-interaction and repeated-exposure data are not established for this preclinical molecule.

What is still unresolved

  • Human exposure, cancer-related pathway risks, repeated-use safety, and interactions remain unestablished.

Side effects & risks

  • FDA reports no identified human exposure data and major safety-information gaps.
  • Effects on a cell-growth signaling pathway require safety evaluation; the mechanism alone cannot establish or exclude cancer risk.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

The central cognition findings come from cell and animal experiments. A separate zebrafish hair-cell study is a different biological model, not evidence of improved human hearing or cognition.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Initial stimulation followed by little effect

A separate commenter described stimulation during the first two experiences, then no noticeable effect on roughly 15 later occasions.

Amount, frequency, route and duration could not be confirmed for this account.

The author account is deleted although the comment remains visible. The report cannot distinguish expectation, product differences or changing response.

Read the fading-effect account
Mixed account · personal report

Initial mental-energy benefit followed by low mood

A commenter described greater mental energy and flexibility initially during oral dihexa exposure, then said that by the fifth week it was making them feel depressed.

Reported use in this account

Product
Product described as oral dihexa
Amount
5 mg
Frequency
Every three days
Route
Oral
Duration
Six weeks

The account is retrospective, and mood, cognition and product contents were not independently assessed. Other substance experiences discussed elsewhere in the thread do not establish simultaneous exposure.

Read the six-week account

Approval status

Dihexa has no FDA-approved therapeutic use. FDA identifies a lack of human exposure information in its dihexa acetate assessment.

Preclinical research; no FDA approval

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Human cognitive benefit
  • Human metabolism and interactions
  • Long-term neurological and cell-growth effects

Summary

Dihexa remains a preclinical research topic; confident claims of human cognitive enhancement exceed the available evidence.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety concerns for selected bulk substances

    Ingredient-specific safety findings; compounding review is not drug approval.

  2. pubmedDihexa and HGF/c-Met-dependent cognitive effects

    Mechanistic and animal cognition experiments.

  3. pubmedDihexa in zebrafish sensory hair cells

    Preclinical protection model, not a human clinical outcome.

How we assess sources · Suggest a correction